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http://www.biomedcentral.com/1472-6882/14/382RESEARCH ARTICLE Open AccessEchium oil is not protective against weight
loss in head and neck cancer patients
undergoing curative radio(chemo)therapy:
a randomised-controlled trial
Lies Pottel1,2,8, Michelle Lycke1,2,8, Tom Boterberg2,8, Hans Pottel3, Laurence Goethals1, Fréderic Duprez2,
Alex Maes4, Stefan Goemaere5, Sylvie Rottey6, Imogen Foubert7 and Philip R Debruyne1,8*Abstract
Background: Therapy-induced mucositis and dysphagia puts head and neck (H&N) cancer patients at increased risk
for developing cachexia. Omega-3 fatty acids (n-3 FA) have been suggested to protect against cachexia. We aimed
to examine if echium oil, a plant source of n-3 FA, could reduce weight loss in H&N cancer patients undergoing
radio(chemo)therapy with curative intent.
Methods: In a double-blind trial, patients were randomly assigned to echium oil (intervention (I) group; 7.5 ml bis in die
(b.i.d.), 235 mg/ml α-linolenic acid (ALA) + 95 mg/ml stearidonic acid (SDA) + 79 mg/ml γ-linolenic acid (GLA)) or n-3 FA
deficient sunflower oil high oleic (control (C) group; 7.5 ml b.i.d.) additional to standard nutritional support during
treatment. Differences in percentage weight loss between both groups were analysed according to the intention-to-treat
principle. Erythrocyte FA profile, body composition, nutritional status and quality of life were collected.
Results: Ninety-one eligible patients were randomised, of whom 83 were evaluable. Dietary supplement adherence was
comparable in both groups (median, I: 87%, C: 81%). At week 4, the I group showed significantly increased values of
erythrocyte n-3 eicosapentanoic acid (EPA, 14% vs −5%) and n-6 GLA (42% vs −20%) compared to the C group, without a
significant change in n-6 arachidonic acid (AA, 2% vs −1%). Intention-to-treat analysis could not reveal a significant
reduction in weight loss related to echium oil consumption (median weight loss, I: 8.9%, C: 7.6%). Also, no significant
improvement was observed in the other evaluated anthropometric parameters.
Conclusions: Echium oil effectively increased erythrocyte EPA and GLA FAs in H&N cancer patients. It failed however to
protect against weight loss, or improve nutritional parameters.
Trial registration: ClinicalTrials.gov Identifier NCT01596933.
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Head and neck (H&N) cancer patients are a nutritionally
vulnerable group because the causative factors alcohol and
nicotine abuse are closely associated with nutritional defi-
ciencies. Moreover, tumour localization and the intensive* Correspondence: Philip.Debruyne@azgroeninge.be
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unless otherwise stated.treatment may induce additional problems (acute dyspha-
gia, nausea, altered taste perception, etc.) resulting in re-
duced food intake and progressive weight loss [1,2]. More
than half of the patients are at risk of malnutrition at time
of treatment presentation, and the majority continues to
lose weight during radiation treatment, with a mean weight
loss of approximately 10% of their body weight [3,4]. Pro-
longed weight loss can, in severe cases, result into cancer
cachexia, a multifactorial wasting syndrome characterized
by anorexia, an ongoing loss of skeletal muscle (with or
without loss of fat mass), neuroendocrine dysfunction andtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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patients with H&N cancer is unknown, but it has been ob-
served in 80% of patients suffering from advanced cancer,
causing death in 20% to 40% of these patients [6]. Several
attempts to improve nutritional status of cancer patients by
conventional oral supplements or parenteral nutrition, were
mostly unsuccessful [7,8]. Recently, long-chain omega-3
polyunsaturated fatty acids (n-3 LCPUFA), especially
eicosapentaenoic acid (EPA), have been suggested to exert
anti-inflammatory properties, through which they could
be effective in reversing cancer cachexia [9,10]. Ryan and
his team demonstrated a significantly attenuated stress
response in the EPA group of surgical esophageal cancer
patients, a population comparable to H&N cancer patients
regarding the underlying mechanisms resulting into a
cachectic state [11]. N-3 PUFA can only be ingested
through the diet, and dietary uptake below recommended
levels has been associated with several Western diseases,
e.g. cardiovascular disease and several inflammatory dis-
eases [12]. Preliminary data have suggested that nutri-
tional intervention with fish oil supplementation, which is
the main source of n-3 LCPUFA, in cancer patients may
lead to weight gain, maintenance of lean body mass, im-
proved performance status and increased appetite in am-
bulatory H&N cancer patients when administered peri- or
postoperatively [13-15]. However, recent in vitro research
suggested that a specific fatty acid component of fish oil
might counteract the efficacy of certain chemotherapeutic
agents [16]. Also, supplement tolerance is often moderate
due to aversion for palatability and occurrence of gastro-
intestinal problems. Moreover, the rapid decline of wild
fish is forcing researchers to look for alternative sources of
n-3 LCPUFA [17-19]. Echium oil is a plant-based alterna-
tive extracted from the seeds of Echium plantagineum,
containing significant amounts of the n-3 PUFA α-
linolenic acid (ALA) and stearidonic acid (SDA), as well as
n-6 PUFA γ-linolenic acid (GLA) and has been suggested
as a true alternative for vegetarians to benefit from the
anti-inflammatory effects of LCPUFA [20]. SDA is the
product of the rate-limiting Δ6-desaturase step and there-
fore more readily converted to EPA, than when consum-
ing ALA (conversion rate 17-30% vs 0.2-8%) [21,22].
Moreover, supplementation with SDA in combination
with GLA has been suggested to work synergistically in
increasing anti-inflammatory effects through increases
in EPA and dihomo-GLA (DGLA) concentrations, and
thereby preventing the accumulation of the pro-
inflammatory arachidonic acid (AA) [23].
In this placebo-controlled, multicentre clinical trial,
we primarily aimed to examine the effect of echium oil
as an alternative source of n-3 PUFA, to reduce weight
loss in H&N cancer patients undergoing curative radio
(chemo)therapy. In addition, we studied the tolerance of
echium oil, its effect on erythrocyte fatty acid profile, aswell as changes in body composition, nutritional status,
treatment-related toxicity and quality of life as second-
ary endpoints.
Methods
Patients
Patients, aged ≥ 18 years, with a histologically confirmed
diagnosis of squamous cell carcinoma of the head and
neck, eligible for curative primary or adjuvant radiother-
apy, with or without systemic treatment were recruited.
Tumours of the parotid gland, nasal cavity, paranasal si-
nuses and patients with cT1 cN0 cM0 glottic cancer were
excluded. Other exclusion criteria were: distant metasta-
ses, another non-cured cancer except for a squamous or
basocellular carcinoma of the skin, a prior radio(chemo)
therapy treatment within the last six months, active intes-
tinal co-morbidity or a known eating disorder precluding
adequate dietary intake or absorption, medicinal use of
anti-coagulants (e.g. warfarin, fenprocoumon, acenocou-
marol, nadroparin (high dose >0.4 ml), enoxaparin
(>40 mg) or tinzaparin) and/or anti-epileptics in case of
history of epilepsy, diagnosis of heart failure, uncon-
trolled diabetes, (severe) dementia, pregnancy or lacta-
tion, use of n-3 FA supplements in the last 4 weeks prior
to enrolment, known allergy for n-3 FA supplements and
inability for adequate communication in Dutch or
French. Patients were consecutively recruited from May
2012 until December 2013 upon presentation at the de-
partments of radiotherapy at General Hospital Groeninge
and Ghent University Hospital. Informed consent was
obtained from all included patients. The trial was ap-
proved by the Ethics Committees of both hospitals.
Study design
Randomisation
A multicentre, placebo-controlled, double-blind trial was
performed. Randomisation was performed at time of en-
rolment to the control group (C) or the intervention
group (I), by minimisation, a method of adaptive stratified
sampling, as described by Pocock and Simon [24]. Gender,
tumour stage, treatment plan and trial site were taken into
account for equal allocation of patients. A random elem-
ent was also incorporated to avoid predictability of the
treatment allocation. An MS Office Excel macro, incorp-
orating abovementioned characteristics, was created by
the designated senior statistician (Prof. H. Pottel) for the
convenience of the study coordinator, who was respon-
sible for the central randomisation of patients.
Dietary supplements
Patients in the I group were asked to consume 7.5 ml bis in
die (b.i.d., twice a day) (15 ml in total) of echium oil (Bio-
Mega SDAW, containing 235 ± 30 mg/ml ALA+ 95 ±
13 mg/ml ALA SDA+ 79 ± 10 mg/ml GLA) daily from
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ment. Patients in the C group received a placebo, contain-
ing the same volume of n-3 PUFA deficient sunflower oil
(Sunflower Oil High Oleic). The complete FA composition
of both dietary supplements is described in Table 1. Biorigi-
nal Food and Science corp. (Bioriginal Europe/Asia B.V.,
Den Bommel, The Netherlands) provided both dietary sup-
plements in a liquid formulation packaged identically in sa-
chets of 7.5 ml volume for convenience of the patient.
Patients were allowed to take the supplements orally or via
an enteral feeding tube if present. Due to the limited stabil-
ity, dietary supplements were delivered in three different
batches, each checked for FA composition consistency by
the Department of Microbial and Molecular Systems (Cath-
olic University Leuven Kulak) as determined by Ryckebosch
et al. [25]. Letter-coded sachets were directly delivered by
the supplier, and presented to the patient after randomisa-
tion by the study coordinator at time of first evaluation.
Only the designated pharmacist of the coordinating centre
possessed the information necessary for decoding, which
was delivered in a sealed envelope by the supplier, and
opened for unblinding after database lock and prior to stat-
istical analyses.
Compliance
Patients were asked to return all unconsumed sachets for
calculation of total dietary supplement intake. In addition,
compliance was verified by collection of a 4 ml EDTA
anti-coagulated blood specimen obtained at baseline and
during week 4 of therapy, at the same time of routine
blood collection, for quantification of erythrocyte n-3 LC
PUFA levels. EDTA blood samples were stored at 4°C
until retrieval by the Cerba European Lab (Brussels,
Belgium) the same day. There, total lipid fraction was re-
moved and injected into the gas–liquid chromatograph
for quantification, according to their in-house protocol.
Results are presented as % of total fatty acid composition.
All fatty acids eluting between myristic acid and docosa-
hexanoic acid were determined.Table 1 Fatty acid composition of dietary supplements
% Total fatty acid composition
Name
BioMega SD
mean
C16:0 Palmitic acid (P) 7.28 ±
C18:0 Stearic acid (S) 3.90 ±
C18:1 (n-9) Oleic acid (O) 15.35
C18:2 (n-6) Linoleic acid (LA) 16.13
C18:3 (n-3) Alpha Linolenic acid (ALA) 31.38
C18:3 (n-6) Gamma Linolenic acid (GLA) 11.00
C18:4 (n-3) Stearidonic acid (SDA) 12.60
C22:1 (n-9) Erucic acid (EA) -
Trans fatty acids -
Abbreviations: I Intervention, C Control.Nutritional status, quality of life assessment and body
composition
Body weight was measured weekly from the start of radi-
ation treatment until treatment end. Patients were
weighed before or after their irradiation, while wearing
light clothing and no shoes. The same scale was applied
for consecutive visits. Body weight loss, as the primary
endpoint, was calculated as ((body weighttreatment start –
body weighttherapy end)/( body weighttreatment start))*100.
For collection of secondary endpoint data, the study
coordinator, assisted by a dietician specialised in oncol-
ogy, assessed nutritional status of every patient at base-
line (week 0, W0), mid-therapy (W4) and at treatment
end (W7) by the Patient-Generated Subjective Global
Assessment (PG-SGA), as this is considered the gold
standard for evaluation of nutritional status in oncology
[26-28]. Higher PG-SGA scores indicate worsened nutri-
tional status. A score of 9 or higher implies “a critical
need for improved symptom management and/or nutri-
ent intervention options”. Additionally, all patients were
asked to self-complete the EORTC quality of life core
questionnaire (QLQ C30) and the H&N cancer specific
(HN35) questionnaire at those three time-points. The
C30 enables assessment of the generic aspects of quality
of life (functional, physical, cognitive, emotional, social
and nutritional status) of cancer patients, while the
HN35 adds H&N cancer specific questions [29,30]. As
an estimate of usual dietary intake, patients were asked
to complete a 3-day-food journal prior to each assess-
ment. Mean total energy and macronutrient (carbohy-
drate, protein, fat, alcohol) intake were calculated with
the Becel Institute Nutrition Software (BINS; Vodisys
Medical Software, Groningen, The Netherlands). This
software uses the Belgian (NUBEL, 1999) and Dutch
(NEVO, 2001) food composition database. Body com-
position was assessed at W0 and at the end of W4, using
both a bioelectrical impedance analyser (BIA 101, Akern S.
r.I., Firenze, Italy), and Dual energy X-ray absorptiometry
(DXA) as the gold standard. Bioimpedance was measuredAW (I group)
± SD
Sunflower oil high oleic (C group)
mean ± SD
0.17 4.00 ± 0.00
0.08 2.88 ± 0.05
± 0.24 84.48 ± 0.05
± 0.10 8.40 ± 0.00
± 0.25 -
± 0.00 -
± 0.22 -
-
-
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400 μA current traveling through source electrodes placed
on the patient’s distal metacarpals while the patient was
lying supine on an examination bed. Resistance, capacitive
reactance and anthropometric values were entered in the
Bodygram ProW software (version 3.0, Akern, Italy) for cal-
culation of fat mass (FM), fat free mass (FFM) and lean
mass (LM). Patients were scanned with the Hologic Discov-
ery Wi QDR Series (S/N 84566; fan-beam, switched pulse
dual-energy x-ray tube, operating at 100 kV and 140 kV) or
the Hologic Discovery A QDR series 4500A (S/N 45018;
fan-beam) in the General Hospital Groeninge (AZG) and
the Ghent University hospital (UZG) respectively. Data
were analysed with the Apex System Software version 3.1.2
(AZG) or the Software version 12.7.3.1:3 (UZG) and col-
lected in a database. A whole body DXA quality control
phantom was scanned ten times on both appliances, for
cross-calibration and calculation of a correction factor, en-
abling correct comparison of the data. Hand grip strength
was measured with the JAMARW hand dynamometer
(Sammons Preston, Bolingbrook, IL, USA), as it is reflective
of muscle mass [31].
Patient demographics, clinical characteristics, and side
effects related to dietary supplements were collected by
the study coordinator through the medical records, and
registered by means of the ‘Common Toxicity Adverse
Event (CTCAE v4.0)’ criteria.
Statistical analysis
Sample size calculations were based on the weight loss be-
tween baseline and end of therapy, of patients who were
recruited in the OMGIANT study (oncogeriatric observa-
tional study in which older H&N cancer patients treated
with curative intent were recruited, NKP_24_018) [32,33].
In this study, an average weight loss of 5.46% (SD 4.63%)
was reported for 38 patients (data not shown). The two-
sided t test was used as a test statistic. The null hypothesis
states that there is no difference between group averages
(average weight loss). In order to show an (absolute) dif-
ference of 3% (i.e. the desired clinical effect) weight loss
between the two groups at 80% power and 5% significance
level, a sample size of 39 (evaluable) patients in each group
was proposed. Prior to recruitment start, the trial was regis-
tered on ClinicalTrials.gov Identifier: NCT01596933. Body
weight loss data of both groups as well as the between-
group difference (effect size), as the primary endpoint, are
expressed both as median (Q1, Q3) and mean ± SD, and
95% confidence intervals (95% CI) were calculated. Mann
Whitney U statistics was applied to look for weight loss dif-
ferences between both groups, according to the intention-
to-treat principle. Secondary endpoint results are expressed
as median (Q1, Q3) due to non-normality of the data.
Mann Whitney U and Wilcoxon Signed Rank test were
performed to explore respectively between- and within-group differences in fatty acid profile, body composition
and grip strength. Spearman correlations were calculated to
look for potential associations between supplement intake,
n-3 LCPUFA changes and weight loss. Wilcoxon Signed
Rank test was applied to explore within-group differences
in nutritional status, caloric intake and quality of life during
treatment, while repeated measures ANOVA models were
established to calculate group differences of the latter pa-
rameters after correction for baseline values, age, gender,
supplement intake, presence of artificial nutrition, tumour
stage, tumour location and treatment. All analyses were
performed using PrismW software (GraphPad Prism 5, Inc.,
La Jolla, CA) and SPSS or SAS software (version 20; IBM
SPSS Statistics, Chicago, IL; SAS Institute Inc., Cary, NC,
USA). Primary endpoint results were considered statistically
significant at P < 0.05. Since the sample size calculation was
only based on the primary endpoint hypothesis, all P-values
obtained from secondary analyses should be considered as
explorative, and thus have a merely suggestive value.
Results
Study population characteristics
Ninety-one eligible patients were enrolled and rando-
mised, of whom 85 effectively started dietary supplement
consumption. Prior to supplement intake, three patients
declined radio(chemo)therapy and three others withdrew
from study participation, one because of a relative who
had advised against trial participation and two because of
lack of understanding associated with non-compliance.
The study population comprised primarily married
(76.5%), male (83.5%) patients, aged 61.0 years old
(range 30 – 81), with an ECOG PS ≤1 (84.7%), and who
were mostly working as an employee (45.9%). Most pa-
tients were current alcohol users (70.6%), with a median
of 3 (1.0, 6.5) consumptions a day, and former smokers
(57.6%) with a median of 30 pack years (14.3, 41.0). Patients
predominantly presented with an advanced stage (III-IVb)
cancer (83.5%) of the pharynx (57.6%), oral cavity (21.2%)
and glottis (15.3%). Five (5.9%) patients presented with re-
gional (lymph node) metastases of an occult primary. Ap-
proximately half of patients (48.2%) were treated with
primary radiochemotherapy (Table 2).
At presentation, patients had a median 6-month-weight
loss of 2.4% (6.3, −1.6), a median BMI of 23.9 kg/m2 (21.3,
27.5), and a median PG-SGA score, as an index for nutri-
tional status, of 9.0 (6.0, 14.0). The median daily caloric in-
take was found to be 1781 kcal (1466, 2231). According to
the definition of Fearon et al. [5] diagnosing patients as
cachectic when a 6-month involuntary weight loss of 5%
or more is present, 31% of study patients were considered
cachectic at therapy initiation. There were no differences
in baseline demographic, clinical or nutritional character-
istics between the I and C group, except for a significantly
lower DGLA fatty acid value in the I group (Table 2).
Table 2 Demographic and clinical characteristics*
Intervention group (I) N = 43 Control group (C) N = 42
Demographic characteristics Median (range)
Age 61.0 (30 – 81) 60.5 (35–79)
Gender n (%)
Male 36 (83.7) 35 (83.3)
Female 7 (16.3) 7 (16.7)
ECOG PS ≤1 34 (79.1) 38 (90.5)
Social status
Married/living together 31 (72.1) 34 (81.0)
Profession
Labourer 18 (41.9) 17 (40.5)
Employee 20 (46.5) 19 (45.2)
Self-employed 5 (11.6) 5 (11.9)
Median (Q1, Q3)
Alcohol consumption (U/day) 4.0 (1.0, 8.0) 3.0 (1.0, 6.3)
Tobacco consumption (PY) 25.5 (8.6, 40.3) 35.0 (17.8, 50.0)
Clinical characteristics n (%)
Tumour location
Oral cavity 11 (25.6) 7 (16.7)
Oropharynx 17 (39.5) 17 (40.5)
Hypopharynx 7 (16.3) 4 (9.5)
Nasopharynx 2 (4.7) 2 (4.8)
Supraglottis 2 (4.7) 7 (16.7)
Glottis 2 (4.7) 2 (4.8)
Occult primary 2 (4.7) 3 (7.1)
Tumour stage
Early stage (I-II) 6 (14.0) 8 (19.0)
Late stage (III-IVb) 37 (86.0) 34 (81.0)
Therapy initiation
Neoadjuvant chemotherapy + radiochemotherapy 2 (4.7) 4 (9.5)
Primary radiotherapy
Alone 7 (16.3) 8 (19.0)
With chemotherapy 22 (51.2) 18 (42.9)
With biotherapy 0 (0.0) 2 (4.8)
Adjuvant radiotherapy
Alone 5 (11.6) 3 (7.1)
With chemotherapy 7 (16.3) 7 (16.7)
With biotherapy 0 (0.0) 0 (0.0)
Nutritional characteristics Median (Q1, Q3)
6-months weight loss (%) 2.5 (6.8, −1.5) 2.2 (5.4, 2.4)
BMI (kg/m2) 22.80 (20.50, 28.70) 24.25 (21.8, 27.2)
PG-SGA score 10.0 (5.0, 15.0) 8.5 (6.8, 13.0)
Caloric intake (kcal/day) 1784 (1449, 2284) 1759 (1531, 2198)
*Both groups did not significantly differ in demographic, nor clinical, nor nutritional characteristics at P < 0.05.
Pottel et al. BMC Complementary and Alternative Medicine 2014, 14:382 Page 5 of 14
http://www.biomedcentral.com/1472-6882/14/382
Table 3 Adherence to dietary supplements
Supplement intake (%) I group
n = 43; n (%)
C group
n = 42; n (%)
100% 8 (18.6) 10 (23.8)
≥ 75% - < 100% 17 (39.5) 16 (38.1)
≥ 50% - < 75% 6 (14.0) 4 (9.5)
≥ 25% - < 50% 2 (4.7) 3 (7.1)
< 25% 10 (23.3) 9 (21.4)
Abbreviations: I intervention, C control.
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(I: 90.7%, C: 88.1%). Of the 85 patients who initiated
dietary supplement consumption, body weight loss was
collected in 83 of them (I: 95.4%, C: 100%; primary end-
point), 77 patients were evaluated at W4 (I: 90.7%, C:
90.5%) and 76 (I: 90.7%, C: 88.1%) at therapy end for
secondary endpoints. A patient allocation flow diagram
is presented in Figure 1.
Nutritional supplement tolerance
The median (Q1, Q3) supplement intake was 86.7% (30.2,
96.0) and 80.6% (43.6, 99.5) of the intended supplement
intake for respectively the I and C group (p = 0.739)
(Table 3). Both the liquid BioMega SDAW and the Sun-
flower oil High Oleic were equally well tolerated, with ap-
proximately three quarter of patients reporting good
tolerance of the dietary supplement (resp. 72.1% vs 71.4%;
p = 1.00). Although no serious adverse events (SAEs) re-
lated to the dietary supplements were reported, reasons
for non-adherence were general non-compliance to the
study protocol or forgetfulness (I: 48.6%, C: 46.9%), stom-
ach ache, nausea, vomiting, and aversion for dietary supple-
ment texture related to radiochemotherapy or strong
opioid pain medication (I: 40.0%, C: 37.5%), and
supplement-related acute diarrhea (I: 2.9%, C: 12.5%). FourFigure 1 Patient allocation flow diagram.patients stopped supplement intake because of respectively
PEG-tube leakage (I: 0.0%, C: 3.1%), inability to swallow liq-
uids after tracheotomy surgery (I: 2.9%, C: 0.0%),
supplement-related appetite loss (I: 2.9%, C: 0.0%) and no
further explained inability to swallow the oil (I: 2.9%, C:
0.0%).
Effect on weight loss (primary endpoint)
Of the eighty-five patients who effectively started nutri-
tional supplement intake, weight loss data at therapy end
were available for 83 patients. Missing data of two patients
was attributed to respectively patient hospitalisation to the
intensive care unit (where data were no longer collected)
and patient death. According to the intention-to-treat
Table 4 Nutritional supplement-related erythrocyte fatty acid profile changes (expressed as% total fatty acid composition; n = 79)*
Fatty acids W0 W4 % change
I C p I C p I C p
n-3
ALA 0.14 (0.11, 0.20)c 0.13 (0.12, 0.18)b NS 0.17 (0.14, 0.23)c 0.12 (0.09, 0.15)b <0.0001 25.40 (−4.50, 63.60) −16.70 (−33.30, 0.00) <0.0001
EPA 0.66 (0.47, 0.81)c 0.68 (0.57, 0.88) NS 0.75 (0.66, 0.90)c 0.62 (0.50, 0.82) 0.02 14.40 (−2.78, 37.78) −5.30 (−21.80, 8.80) <0.001
n-6
LA 6.72 (5.94, 7.49)d 6.71 (5.88, 7.44)a NS 6.03 (5.25, 6.81)d 6.68 (5.71, 7.16)a NS −8.35 (−15.38, −2.48) −3.80 (−9.60, 3.50) 0.02
GLA 0.04 (0.02, 0.05)b 0.05 (0.03, 0.06)a NS 0.06 (0.04, 0.07)b 0.03 (0.02, 0.06)a <0.01 41.65 (−20.00, 133.3) −20.00 (−50.00, 16.70) <0.001
DGLA 1.21 (1.13, 1.42)d 1.34 (1.21, 1.65) 0.04 1.52 (1.22, 1.78)d 1.36 (1.14, 1.68) NS 18.75 (1.75, 35.30) 2.40 (−6.20, 6.80) <0.0001
AA 12.84 (11.39, 13.35) 12.80 (11.72, 13.50) NS 12.78 (11.77, 13.37) 12.71 (11.71, 13.64) NS 2.35 (−2.05, 7.13) −0.80 (−5.30, 5.00) NS
*Data presented as median (Q1, Q3). Within-group significant differences were indicated by letters a (p < 0.05), b (p < 0.01), c (p < 0.001), d (p < 0.0001). Five patients refused second blood analysis, one was admitted to
ICU. Significant P-values provided in bold.
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cant difference in weight loss was observed between the I
group (n = 41, median (Q1, Q3); 8.9% (4.6, 11.8); mean ±
SD (95% CI) 8.1 ± 5.4 [95% CI (6.5, 9.8)]) and the C group
(n = 42, 7.6% (4.9, 9.8); 7.0 ± 5.1 [95% CI (5.4, 8.6)])
(p = 0.303). The body weight loss difference between both
groups, or the effect size, was 1.13 [95% CI (−1.16, 3.42)]. A
comparable percentage of patients in both groups required
hospitalisation for artificial nutritional support (I: 18.6%, C:
26.8%, p = 0.439).
Spearman correlations only revealed a negative associ-
ation (rs = − 0.47, p < 0.01) between supplement intake
and weight loss in the I group. Percentage weight loss
was also found to negatively correlate with changes in
ALA (rs = − 0.42, p < 0.01), EPA (rs = − 0.41, p < 0.01),
and DGLA (rs = − 0.37, p < 0.05) in the I group. In the
C-group weight loss negatively correlated with GLA
(rs = −0.48, p = p < 0.01).
Effect on erythrocyte fatty acid profile
Prior to nutritional supplement intake no significant dif-
ferences were observed in the fatty acid profiles of both
groups, except for a significantly lower DGLA value in
the I group (Table 4).
After 4 weeks, echium oil intake led to significant me-
dian increases in ALA (25.4%), EPA (14.4%), GLA
(41.7%), DGLA (18.8%), a non-significant median in-
crease in AA (2.4%), and a significant median decrease
in LA (−8.4%) compared to baseline. In the C group me-
dian reductions in all FAs were seen, except for DGLA.
The relative change over time of all FAs significantly dif-
fered between the I and C group, except for AA
(Table 4). These changes resulted in significantly higher
absolute values of ALA, EPA, and GLA in the I group
compared to the C group, but comparable values of LA,
AA and DGLA. The latter could be attributed to the sig-
nificant lower DGLA concentration that was observed at
baseline in the I group. In the I group, a dose–response
relation was observed between the amount of dietary
supplement ingested and changes in n-3 ALA (rs = 0.51,
p < 0.001), n-3 EPA (rs = 0.39, p < 0.05) and n-6 DGLA
(rs = 0.57, p < 0.001) (Figure 2). No significant correla-
tions were observed in the C group.
Effect on other anthropometric parameters
No significant differences in baseline fat free mass
(FFM), fat mass (FM), lean mass (LM), and grip strength
were observed between both groups, assessed with DXA,
BIA and JAMAR® hand dynamometer respectively. After
4 weeks of dietary supplement intake, a significant de-
crease in FFM (I: median −5.10%, C: −4.12%, P < 0.01)
and LM (I: −3.77%, C: −2.41%, P < 0.01) was observed in
both groups with DXA. A respectively significant and
borderline significant decrease in FM was observed inthe I (−4.04%, P < 0.05) and C (−3.66%, P = 0.05) group.
The relative change of FFM, LM and FM compared to
baseline did not significantly differ between both groups.
BIA measurement revealed a significant relative increase
in FM in the I group, compared to the C group (10.55%
vs −3.90%, P < 0.05). The relative median decrease in
grip strength throughout treatment was comparable be-
tween both groups (I: −0.86% vs C: −0.78%, P > 0.05).
Prior to treatment start, both groups did not signifi-
cantly differ in nutritional status or caloric intake. Radio
(chemo)therapy had a significant negative impact on nu-
tritional status, measured as PG-SGA, at W4 in both
groups, and this remained stable until the end of treat-
ment (data not shown). Reported dietary intake showed
a decrease in caloric intake in both groups, however no
statistically significant intervention effect was observed
between the I and C group after correction for age,
weight, length, gender, tumour location, tumour stage,
and supplement intake (data not shown).
Effect on quality of life and treatment-related toxicity
The percentage of severe-grade treatment-related tox-
icity was not significantly different in the I group, com-
pared to the C group (51.2% vs 69.0%; p = 0.122). A
comparable number of patients of respectively the I and
C group required hospitalisation (I: 27.9%, C: 35.7%;
p = 0.490). None of the SAEs that occurred were consid-
ered to be due to dietary supplementation but more
likely to be attributed to therapy-related toxicity or dis-
ease progression.
Self-reported quality of life, assessed with EORTC
QLQ C30 and HN35, was analysed through a repeated
measures ANOVA model, in which baseline QOL status
was incorporated as a covariate, as well as age, gender,
tumour location, tumour stage, initiated treatment and
supplement intake as potential confounders. No signifi-
cant difference in function or symptom scores was ob-
served between both groups (data not shown). A
recurrent data pattern, however, demonstrating a posi-
tive relation between supplement intake and respectively
nutritional status and EORTC QLQ function scores, as
well as an inverse relation between supplement intake
and EORTC symptom scores was observed irrespective
of the study group (data not shown).
Discussion
H&N cancer patients are a nutritionally vulnerable
population at increased risk of developing cancer cach-
exia. Conventional nutritional support has at present not
succeeded in reversing the cachectic state. Recently, n-3
LCPUFA EPA under the form of fish oil has demon-
strated anti-inflammatory properties that improved nu-
tritional parameters in cancer patients. In latest years,
the decline of wild fish stocks in combination with the
Figure 2 Percent change in erythrocyte fatty acid profile after dietary supplement consumption. The I and C group values are presented
as respectively red squares and blue diamonds, and the resp. full and dashed line. A. Percent change in EPA in I (r 0.50, P < 0.01) and C (r −0.17,
P > 0.05), B. Percent change in DGLA in I (r 0.60, P < 0.0001) and C (r −0.24, P > 0.05), C. Percent change in ALA in I (r 0.43, P < 0.01) and C (r −0.19,
P > 0.05), and D. Percent change in AA in I (r 0.16, P > 0.05) and C (r −0.28, P > 0.05). EPA: eicosapentaenoic acid, ALA: α-linolenic acid, DGLA:
dihomo-γ-linolenic acid, AA: arachidonic acid.
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domains has stimulated the search for alternative sources
of n-3 LCPUFA. In the present study, a clear increase in n-
3 ALA and EPA, as well as n-6 GLA and DGLA were ob-
served after echium oil consumption, at the median dose
taken, without a significant increase in AA. Nevertheless,
the intervention proved ineffective in reducing weight loss
during radio(chemo)therapy. Also, no significant improve-
ment in preservation of lean mass, nutritional status, hospi-
talisation requirement and self-reported quality of life was
observed. To our knowledge, this is the first trial to report
the effects of a plant n-3 PUFA supplement in a cancer
population. Echium oil has been suggested as a good alter-
native to fish oil for vegetarians [20], since it contains high
levels of ALA and SDA, which are converted to EPA. Diet-
ary intake of ALA and SDA results in a 0.2-8% and 17-30%
conversion to EPA, respectively, depending on both the
lipid fraction studied and the absolute ALA or SDA
intake of supplements administrated [21,34-37]. More-
over, the high GLA content is said to reinforce the anti-
inflammatory effects produced by EPA, through its
metabolite DGLA. At the dose volume taken medianerythrocyte EPA content increased approximately 14%,
with a maximum of 103% after 4 weeks, while a 40% in-
crease in GLA lead to an approximate 20% increase in
DGLA. Although the daily echium oil volume comprised
3.5 g ALA and 1.4 g SDA, the median EPA increase ob-
served is lower than the 20% and 75% EPA increase re-
ported in healthy subjects after respectively 1.5 g and 1.3 g
SDA consumption daily for 3 and 4 weeks [21,35,38]. The
large variability that is seen in FA changes over time, could
be related to variations in supplement adherence as well as
the significant decline in caloric intake in general, and lipid
intake in specific, hampering n-3 PUFA uptake [39-41].
Also non-dietary factors could be involved, such as absorp-
tion, metabolism, and genetic and lifestyle determinants
that are known to affect FA concentrations in human tis-
sues [42]. Although controversial, alcohol and smoking sta-
tus has been reported to negatively impact FA profile
[43,44], and higher BMI was recently described to be asso-
ciated with lower relative and net increases in EPA [45].
Although a significant median increase was observed,
EPA and DGLA concentrations might however still have
been insufficient to reverse weight loss. Previous trials
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3 to 8 weeks to be associated with beneficial effects on
nutritional parameters [46,47]. The latter increases are
mostly measured in plasma phospholipids, which are
much more sensitive to the last dietary intake than red
blood cells, and might therefore not be adequately com-
pared. However, Arterburn et al. reported a strong cor-
relation between plasma phospholipid and red blood cell
EPA contents [42]. Based on conversion rates observed
in healthy patients [35,37], one could argue that con-
sumption of the echium oil volume as applied in our
trial would result into a daily EPA dosage that is ap-
proximately half of the minimum effective dosage of
1.5 g suggested in previous publications [48,49]. How-
ever, we hypothesized that the additional DGLA increase
might be sufficient to exert comparable effects as seen
with fish oil, since attenuation of body weight loss and
reversal of tumour-induced lipolysis has been demon-
strated in mice fed a diet supplemented with SDA and
GLA [50,51]. Moreover, one clinical trial randomising
patients with acute lung injury between standard iso-
nitrogenous and isocaloric enteral nutrition alone or
combined with EPA and GLA for a period of 14 days
showed improved oxygenation, and higher BMI in the
experimental group [52]. According to the current pub-
lished conversion rates [35,37], the required daily
echium oil volume intake would significantly have to in-
crease in order to obtain comparable dosages of EPA as
found in fish oil (e.g. 2.4 g EPA would require 60 ml
echium oil). However, this might still not show the
intended EPA increase since diets containing above-
optimal levels of n-3 PUFA might not lead to a further
increase in EPA in humans, given that the most efficient
conversion rates are on n-3 PUFA deficient diets [53].
At the median dose taken, cases of abdominal discom-
fort and belching have been reported, although they
were mostly attributed to chemotherapy-related general
nausea resulting in an aversion for the dietary supple-
ment texture. Intake of larger volumes of echium oil
might not be feasible under radiochemotherapy condi-
tions. Furthermore, increased volumes of echium oil are
associated with larger GLA dosages. The current esti-
mated EPA:GLA ratio of 0.67:1 did not show a signifi-
cant increase in AA at week 4, which is in agreement
with Geppert et al. reporting preservation of AA values
after GLA consumption in a EPA:GLA ratio of 0.2:1
[54]. However, to avoid a negative shift towards in-
creased n-6 LCPUFA AA values, GLA dosage was kept
within acceptable ranges [55].
Although progressive weight loss seen in our trial is com-
parable to non-intervention trials in H&N cancer patients
reporting mean weight losses of 5.7% to 10%, Spearman
correlations are suggestive for a positive effect of ALA, EPA
and DGLA on weight loss. Prior trials reporting improvednutritional status related to EPA in H&N and esophageal
cancer patients provided n-3 LCPUFA enriched protein-
and energy-dense nutritional supplements for approxi-
mately 4 to 12 weeks peri- or postoperatively to improve
caloric intake and stimulate lean mass anabolism
[11,13,14]. Since in our trial oral nutritional supplementa-
tion was presented at time of weight loss initiation, and
since it is difficult to differentiate whether the ongoing
weight loss is related to tumour- or treatment-related dys-
phagia rather than anorexia or systemic inflammation due
to metabolic changes, it could be possible that underlying
starvation mechanisms might have limited the effectiveness
of the current intervention [56]. However, although a sig-
nificant decline in caloric intake – comparable with litera-
ture [57,58] – was observed, no significant differences in
caloric intake that could have had an impact on weight loss
were seen between both groups. Moreover, the inter-
national consensus definition that was established for can-
cer cachexia by Fearon et al. does not suggest an alternative
definition for both H&N or esophageal cancer, in which re-
duced food intake secondary to dysphagia is common [5].
Although prophylactic energy-dense nutritional supple-
mentation is not standard, it might have improved the tol-
erance of dietary supplements and retained caloric intake
potentially reducing weight loss during intensive radio
(chemo)therapy, since four trials were recently published
that showed (tendencies towards) improvement in body cell
mass [59], body weight [60,61], and metabolic, inflamma-
tory and oxidative stress parameters [62] in H&N cancer
patients under radio(chemo)therapy after administration of
prophylactic enteral nutrition or high caloric oral nutri-
tional supplements enriched with n-3 PUFA, and specific
micronutrients or probiotics.
The significant decrease in lean mass seen in both
groups, could be attributed to the decline in protein in-
take. The relative increase in fat mass, as measured by
BIA was, however, not confirmed by DXA, which was
used as gold standard. Since FM is calculated from FFM,
this increase could be relative to the decrease in FFM
seen in these patients. Moreover, dehydration is com-
mon in H&N cancer patients under radiochemotherapy,
and can lead to an overestimation of fat mass measure-
ments by BIA [63,64]. PG-SGA scores, as a measure of
nutritional status, increased equally throughout treat-
ment in both groups, as did EORTC symptom scores.
EORTC function scores decreased significantly at each
time-point. This is in line with prior reports by our own
research group [33]. Remarkably, a comparable “effect”
of supplement intake on PG-SGA scores, EORTC func-
tion scales, and symptom scales ‘dry mouth’, ‘general feel-
ings of illness’, ‘nausea and vomiting’ and ‘sticky saliva’ in
specific, was seen in both groups. I.e., patients with a
dietary supplement intake of 75% or more showed lower
PG-SGA and EORTC symptom scores, while higher
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less than 75% of the supplements. Since these results are
corrected for parameters influencing treatment toxicity,
this could suggest that patients with the best understand-
ing of the severity of their disease are the most motivated
and treatment-compliant, and thus also the ones most ad-
herent to the dietary supplement.
Our study results should be interpreted with caution
due to some study limitations. First, the typical western
diet already contains high levels of especially n-6 PUFA
(ratio n-6/n-3 is 20:1) [65]. However, since we could not
control the type of dietary fat in the background diet,
this could be partly responsible for the strong variations
seen in fatty acid profile at week 4. Also, patients with a
percutaneous endoscopic gastrostomy (PEG) tube were
not excluded from trial participation. Moreover, several
patients required PEG-tube placement during therapy
because of prolonged weight loss, and enteral nutrition
can sometimes be enriched with n-3 LCPUFA. The
number of patients with a prophylactic PEG-tube, or re-
quiring one during treatment, did not significantly differ
in both groups. Moreover, subgroup analyses excluding
patients fed with enteral or parenteral nutrition were not
suggestive for a change in trial results (data not shown).
Second, four weeks of high oleic sunflower oil consump-
tion (10.4 g oleic acid/day) seemed to lead to decreased
values of both n-3 and n-6 PUFA, except for DGLA,
which could be responsible for the significant difference
in (LC)PUFA concentrations between both groups. This
is not in agreement with literature, reporting comparable
n-3 LCPUFA at both time points in the placebo group in
non-small cell lung cancer patients during multimodality
treatment [66,67]. Indeed, this decline could be related
to the strong decrease in caloric intake that is inherently
seen in H&N cancer patients during treatment, since ad-
ministration of 8.5 g high oleic sunflower oil over a 12-
week period, did not change (LC)PUFA concentrations
in a healthy population with a stable energy intake [34].
Moreover, Dessi et al. reported that nutritional
deprivation in hemodialysis patients was associated with
decreased PUFA abundance [39]. Subgroup analysis of
those patients consuming less than 25% of the dietary
supplement, were also suggestive for median decreased
LCPUFA values (data not shown). Third, non-adherence
to the dietary supplement did not lead to exclusion since
the primary endpoint was analysed according to the
intention-to-treat principle for which our trial was suffi-
ciently powered. This was different than a publication by
Murphy et al. who excluded patients with a supplement
intake of less than 80% [66]. Patient adherence to the
nutritional supplements was only moderate, however
comparable in both groups. H&N cancer patients are
known to lack motivation to comply with treatment or
supportive care associated with it, and many will notcomplete clinical trials impeding accurate trial results
[57,68]. Comparable recurrent PG-SGA and EORTC
QOL data patterns associated with supplement intake in
both groups, confirm the potential bias created by pa-
tient non-adherence. Administration of echium oil
already at time of diagnosis or as of radio(chemo)therapy
end, may possibly increase patient adherence potentially
leading to higher erythrocyte EPA increases and associ-
ated anti-inflammatory effects, and might therefore be
worth exploring in the future. Fourth, we did not meas-
ure any inflammatory markers that could indicate if the
median dose volume consumed did in fact improve sys-
temic inflammation. Retrospective analysis of raw C-
reactive protein (CRP) data collected during routine
blood analyses at W4 showed median CRP increases in
both groups during treatment (n = 60, I: 4.5 (−0.0, 12.0)
and C: 1.4 (−2.0, 11.7)), while no significant difference in
absolute CRP change was observed between both groups
(P = 0.40). Last, we did not correct for multiple testing
through application of the ‘α spending function’, since
this correction primarily applies to multiple primary
endpoints and since this would be extremely difficult
considering the multitude of different statistical tests
employed [69]. All secondary endpoint results are, there-
fore, to be considered as merely suggestive.
Conclusions
In conclusion, echium oil supplementation was feasible,
well-tolerated and – despite moderate adherence – intake
resulted in the anticipated increase of erythrocyte EPA and
DGLA, without a significant increase in AA. Echium oil,
however, failed to protect against radio(chemo)therapy-in-
duced weight loss in our study, and should therefore not
yet be recommended in daily practice, outside of the con-
text of a clinical trial.
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